Repligen Co. (NASDAQ:RGEN) Shares Bought by IFM Investors Pty Ltd

IFM Investors Pty Ltd lifted its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 5.2% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 11,193 shares of the biotechnology company’s stock after purchasing an additional 553 shares during the quarter. IFM Investors Pty Ltd’s holdings in Repligen were worth $2,059,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Park Place Capital Corp increased its stake in shares of Repligen by 90.2% during the 3rd quarter. Park Place Capital Corp now owns 253 shares of the biotechnology company’s stock valued at $40,000 after acquiring an additional 120 shares during the last quarter. Benjamin F. Edwards & Company Inc. grew its holdings in Repligen by 152.1% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 242 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 146 shares during the period. Signaturefd LLC increased its position in Repligen by 44.1% during the third quarter. Signaturefd LLC now owns 281 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 86 shares during the last quarter. Principal Securities Inc. purchased a new position in Repligen during the fourth quarter worth approximately $48,000. Finally, Milestone Investment Advisors LLC acquired a new position in shares of Repligen in the 3rd quarter valued at $61,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Insider Buying and Selling

In other news, CEO Anthony Hunt sold 16,707 shares of the stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $197.44, for a total transaction of $3,298,630.08. Following the transaction, the chief executive officer now owns 185,249 shares of the company’s stock, valued at $36,575,562.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Repligen news, VP Ralf Kuriyel sold 3,517 shares of Repligen stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $193.73, for a total value of $681,348.41. Following the completion of the transaction, the vice president now directly owns 24,260 shares in the company, valued at $4,699,889.80. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Anthony Hunt sold 16,707 shares of the stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $197.44, for a total value of $3,298,630.08. Following the sale, the chief executive officer now owns 185,249 shares in the company, valued at $36,575,562.56. The disclosure for this sale can be found here. Over the last quarter, insiders sold 25,597 shares of company stock worth $5,039,532. Insiders own 1.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on RGEN shares. Stifel Nicolaus increased their target price on Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a research report on Thursday, February 22nd. KeyCorp raised their price objective on Repligen from $210.00 to $220.00 and gave the stock an “overweight” rating in a report on Thursday, February 15th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, Repligen has an average rating of “Moderate Buy” and an average target price of $196.70.

Repligen Stock Up 0.6 %

Shares of RGEN stock traded up $0.92 during trading hours on Friday, reaching $166.58. The company had a trading volume of 341,269 shares, compared to its average volume of 463,708. The company has a market capitalization of $9.30 billion, a P/E ratio of 231.36, a price-to-earnings-growth ratio of 5.42 and a beta of 1.02. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.75 and a current ratio of 7.02. Repligen Co. has a twelve month low of $110.45 and a twelve month high of $211.13. The stock’s fifty day simple moving average is $184.21 and its 200 day simple moving average is $173.55.

Repligen (NASDAQ:RGEN) last posted its earnings results on Wednesday, February 21st. The biotechnology company reported $0.33 EPS for the quarter, hitting analysts’ consensus estimates of $0.33. Repligen had a net margin of 6.51% and a return on equity of 5.00%. The business had revenue of $155.74 million for the quarter, compared to analysts’ expectations of $155.38 million. During the same period in the previous year, the company posted $0.68 earnings per share. The business’s revenue for the quarter was down 16.6% compared to the same quarter last year. As a group, sell-side analysts expect that Repligen Co. will post 1.46 earnings per share for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.